Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
26. Juli 2022 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
12. Januar 2022 07:05 ET
|
Apollomics, Inc.
FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
04. Januar 2022 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
22. November 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial
30. September 2021 07:10 ET
|
Apollomics, Inc.; Edison Oncology Holding Corp.
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies...
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
10. August 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China and SHANGHAI, China, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of...
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
09. März 2021 07:10 ET
|
Apollomics, Inc.
- Fibrogen veteran brings global R&D expertise to Management Team - - Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy...
Apollomics, Inc. Announces Successful Enrollment of First Patient Into Phase 1 Clinical Trial of APL-106 (Uproleselan Injection) in China
04. März 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
12. Februar 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study
12. November 2020 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting...